NEW YORK, Oct. 17 (GenomeWeb News) - San Diego-based Diversa and Princeton, NJ-based Medarex yesterday announced they have entered into an R&D collaboration to develop and optimize antibodies to be used as drug targets.
Registering provides access to this and other free content.
Already have an account?Login Now.
Researchers suggest that genetic variations could influence the side effects people experience when using synthetic cannabinoids, the International Business Times reports.
An analysis has examined the makeup of researchers on Twitter and what they share, Nature News reports.
At Stat News, Jim Kozubek argues that the Broad Institute is pushing the boundary of what a nonprofit is.
In PNAS this week: gut microbes may affect honeybee weight, phenotype and gene expression changes in DiGeorge syndrome, and more.